2132 POSTER Economic impact of adding capecitabine (X) to docetaxel (T) and trastuzumab (H) as first-line therapy for HER2-positive advanced or metastatic breast cancer

✍ Scribed by A. Bonetti; A. Santoro; P. Ducournau; A. Cirrincione; G. Giuliani; R. Bell

• Book ID: 118625736
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 57 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)70894-7